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Introduction
The shortage of functional information compared to
the abundance of sequence information character-
izes today’s situation in functional genomics. For
many years the knock-down of a gene’s product
has been the most powerful way of analysing its
function. In addition to the complete knock-out by
homologous recombination, several different tech-
niques have been developed to temporarily knock
down gene expression through methods based
on speciﬁc sequence recognition, such as knock-
down by antisense oligonucleotides, ribozymes,
aptamers or RNAi.
The ESF workshop on ‘Impact of Nucleic Acid
Chemistry on Gene Function Analysis’ brought
together researchers who use techniques that are
different but highly related. It offered an opportu-
nity for an in-depth discussion of recent progress
and common problems. Antisense oligonucleotides,
aptamers and ribozymes are techniques that have
been used successfully for many years to validate
targets. However, recent developments, such as
increased tightness of binding (e.g. locked nucleic
acids) or the combination of different methods (e.g.
using aptamers to design ribozymes), have con-
tinued to improve the existing techniques. RNA
interference (RNAi) is a defence mechanism of
the cell against viruses. Since the exact mech-
anism of action within the cell is still unclear,
RNAi was a particularly exciting topic at the
workshop and was addressed in the largest num-
ber of presentations. Predictability of positional
effects (accessibility of RNA) is a problem shared
by all techniques using sequence-speciﬁc recog-
nition and was the subject of quite controver-
sial debates.
The meeting comprised over 50 people from
14 countries (13 European countries and the
USA).
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Session on antisense approaches and
accessibility of RNA
Susan M. Freier (Isis Pharmaceuticals, Carls-
bad, USA) gave an overview of the three different
mechanisms of antisense oligonucleotides: RNase
H mechanism, occupancy only, and non-RNase H
cleavage. During her presentation, many parame-
ters were discussed with respect to optimal site
selection for antisense oligonucleotides. Oligos tar-
geted to some feature types (UTR, CDS, intron)
are active, but correlations still remain difﬁcult,
e.g. binding (thermodynamic processes) at a sin-
gle site correlates with antisense activity. It could
be demonstrated that calculated duplex free energy
and sequence motifs correlate with the message
inhibition. For antisense oligo design, additional
aspects have to be considered, e.g. target speci-
ﬁcity (are all isoforms known?), other species and
certain motifs that support a non-antisense effect
(e.g. G-quartets) [11]. In summary, it was stated
that no single parameter demonstrated high cor-
relation with cellular antisense activity, but each
parameter could offer an improvement on the ‘hit
rate’ and combinations of parameters could signif-
icantly improve hit rates.
Non-RNase H mechanisms: oligos selected for
non-RNase H mechanisms could re-direct splic-
ing to produce a variant mRNA and could redirect
polyadenylation [15] when targeting polyadenyla-
tion signals. In addition, oligos targeting the 5  cap
could inhibit translation and RNA ‘gap-mers’ could
be used to cleave target mRNA.
Michael Gait (Medical Research Council,
Cambridge, UK) presented HIV-1 TAR (transacti-
vation responsive element) as a target for inhibition
by antisense oligos. Efﬁcient inhibition of TAR
RNA in HeLa cell nuclear extracts was proven for
oligos such as 2 -O-methyl-oligoribonucleotides
(OMe), chimeric OMe/LNA oligos and PNA.
TAR binding strength was shown to be depen-
dent on buffer conditions, and oligo concentra-
tions of 100–200 nM resulted in 50% inhibition of
transcription. The attachment of FAM was intro-
duced as a new general procedure for synthesis
of 3 -labelled oligonucleotides. For delivery into
cells, the group tested different delivery systems in
HeLa cells stably transfected with three plasmids
(TAT gene, ﬁreﬂy luciferase and Renilla luciferase
under three different promoters) [1]. Also of inter-
est is a new class of cationic gemini surfactants,
including a new compound from GlaxoSmithKline
(GS 11) [12] which has proved to be very efﬁ-
cient. In the last part of the presentation, Mike Gait
introduced a delivery system using peptide con-
jugates for cell translocation by a non-endosomal
route. The strategy for conjugation was proposed
as a total stepwise solid-phase synthesis of pep-
tide–oligo conjugates.
Georg Szakiel (Institute for Molecular Medi-
cine, L¨ ubeck, Germany) described a new concept
of computational antisense oligo design based on a
systematic analysis of secondary structure predic-
tions of target RNA. For improved cellular deliv-
ery, a hybrid approach of additional nucleotide
sequence elements combined with an indicator
gene showed the feasibility of this system.
Judith van Deutekom (Leiden University Me-
dical Centre, The Netherlands) presented work
on a sequence-based exon-skip therapy for Du-
chenne muscular dystrophy (DMD). Dystrophin
frame-shift mutations cause different forms of
mild (Becker muscular dystrophy, BMD) or severe
(DMD) muscle degeneration. Antisense oligos
were used to correct these back into frame
by inducing exon skipping. This led to normal
amounts of properly localized dystrophin in a
mouse model with DMD patient-derived muscle
cells. The future could be a gene correction therapy
using antisense oligos for exon skipping.
Stefan Amberg (University of Frankfurt, Ger-
many) discussed the inhibition of hepatitis C viral
gene expression by differently modiﬁed antisense
oligos. The oligodeoxynucleotides (ODNs) had
polar (phosphorothioate) or non-polar (benzyl-, 2-
phenylethyl-, 4-phenylbutylphosphonate) modiﬁca-
tions and were synthesized via phosphoramidite
chemistry. The best inhibitory effect in vitro and
in cell culture (HepG2) was demonstrated for ter-
minally modiﬁed benzyl-oligodeoxynucleotides.
Gunther Hartmann (University of Munich,
Germany) addressed the modulation of malignant
B cell activation and bcl-2-mediated apoptosis by
antisense ODN and immunostimulatory CpG ODN
(ODN containing unmethylated CG-dinucleotides).
In the mouse tumour model, it was demonstrated
that CpG ODN has potential as a therapeutic due
to its immunostimulatory properties.
Bertrand Tavitian (INSERM Orsay, France)
ﬁnished the ﬁrst session by demonstrating a dif-
ferent use of oligos, namely by adapting oligos
as radiotracers for positron emission tomography
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(PET). The sensitivity of PET combined with radio-
labelled oligos to address gene expression resulted
in an impressive application in animal tumour mod-
els. Several video clips demonstrated the potential
of this imaging technology.
Session on RNAi in plants and model
organisms
Scott M. Hammond (Cold Spring Harbor Lab-
oratory, New York, USA) brieﬂy described the
history of RNA interference, with emphasis on the
founder articles by Fire et al. [5] and on the discov-
ery of short interfering RNA (siRNA) by Hamilton
and Baulcombe [6], before going on to describe
the biochemical characterization work on RNAi
components done by Gregory Hannon’s group [7,
2, 8]. In short, deﬁning the RNase-III-like nucle-
ase Dicer, deﬁning the mRNA degrading com-
plex RISC, and ﬁnally, isolating enough of the
RISC complex to allow microsequencing of com-
ponents, thereby ﬁnding the PAZ/PIWI protein
Ago-2. Unpublished work described included the
microsequencing of another RISC component, Vig,
which has no known domains, but which has a
human homologue that is known to bind mRNA,
and one component, CG7008, that is a poten-
tial candidate for the actual mRNA cleaving pro-
tein, termed SLICER. Future applications described
by Hammond included: (a) a cost-effective T7-
based expression system for production of siRNA
from short DNA templates; (b) a plasmid construct,
pSHAG, for expressing short hairpins that are
processed to siRNA; and (c) an informatic/high-
throughput scheme for screening large numbers
of genes (selected sets, e.g. in cancer, apoptosis,
lethality, drug research) in vivo by transfecting in
T7 transcribed siRNA in 96-well plates.
Marcel Tijsterman (Netherlands Institute for
Developmental Biology, Utrecht, The Nether-
lands) related the discovery in Ronald Plasterk’s
group of the linkage between mutator C. elegans
strains containing activated transposons and RNA
silencing [10, 13, 14]. The isolated mutants were
shown to be homologues of genes involved in
RNAi in other organisms, notably rde-1, rde-4 and
mut-7. Turning the focus to RNA interference in
C. elegans, more mutants and/or homologues of
known RNAi genes were investigated, uncovering
the basic mechanisms of siRNA production in vivo
and sterility of Dcr-mutants, and mapping pathways
of genes needed for siRNA production. A remark-
able mechanism producing new siRNA by extend-
ing 21–40 nt antisense RNAs on an mRNA tem-
plate was discovered, termed ‘transitive RNA’ or
‘secondary siRNA’. The RdRP-homologues rrf-1,
rrf-2 and rrf-3, seem to be involved, with rrf-1
being necessary and rrf-3 actually seeming to be
an inhibitor of RNAi, making the rrf-3 strain inter-
esting for enhanced RNA interference screens in
C. elegans.
Martin Tabler (Institute of Molecular Biol-
ogy and Biotechnology, Heraklion, Greece) cov-
ered three topics. In the ﬁrst section the effects
of various modiﬁcations on the activity of anti-
notch siRNAs were reported [3]. The absence of
5  phosphate lowered penetrance of the Notch phe-
notype but did not affect its expressivity. siRNAs
were found to be tolerant for a single mutation,
while a double-mutation signiﬁcantly lowered both
penetrance and expressivity. DNA was not toler-
ated in either strand of the siRNA. Tabler then
proceeded to describe the expression of a ‘pan-
handle’ dsRNA in transgenic N. tabacum plants.
These transgenic plants displayed three different
phenotypes, in which the degree of virus resistance
correlated with the expression of transgene-derived
siRNAs. Silencing was further found to be sta-
ble between T0 and T1 generations. Finally, the
induction of RNAi in C. elegans embryos follow-
ing injection of an extract prepared from silenced
plants was reported [4]. Following size fraction-
ation of the extract, the highest silencing activ-
ity was found in the 81–90 nt size range. The
RNA responsible for this activity appeared to be
present at very low concentration. Tabler concluded
his presentation by hypothesizing that a hairpin
RNA of 85 nt, resulting from aberrant transcrip-
tion, might be responsible for systemic spreading
of silencing.
In a short presentation, Yuanhuai Han (Univer-
sity of Nottingham, UK) reported inverted repeat
(IR)-dependent silencing of an ACC oxidase 1
sense transgene in tomato plants [9]. Silencing was
accompanied by the production of small antisense
RNAs of 21–28 nt. These asRNAs were present
at much higher concentrations with the sense than
the antisense transgene. Furthermore, the asRNAs
appeared to be produced preferentially from the 5 
end of the gene.
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Session on RNAi in mammalian cells and
humans
Tom Tuschl (Max Planck Institute for Biophys-
ical Chemistry, G¨ ottingen, Germany) gave an
overview of the extensive work his group has done
on RNAi in mammalian cells. When using short,
approximately 21 nt RNA instead of long RNA, no
interferon response is triggered in the cells. Opti-
mal results are obtained with 2 nt 3  overhangs and
starting with a G at the upstream end. He demon-
strated that the cleavage of siRNA is exactly in
the middle of the sequence and excluded the gen-
eration of secondary siRNA species. The second
part of his talk focused on microRNA. MicroRNAs
are excised from 30 bp stem–loop structures by
a mechanism related to RNAi. They may func-
tion as negative regulators, guiding nucleases to
homologous mRNA. Cloning and sequencing of
endogenous RNAs led to the identiﬁcation of about
70 novel microRNAs.
Mohammed Amarzguioui (Biotechnology
Centre of Oslo, Norway) discussed the efﬁcacy
and duration of RNAi in mammalian cells in
respect to several parameters. He observed strong
positional effects that did not correlate with the
predicted target site secondary structure or siRNA
GC content. Mismatches were tolerated in siRNA,
resulting in gradual attenuation in the rate and
extent of depletion. The silencing effect in his
experiments was transient, reaching its maximum
after 24 h and recovering gradually after 72 h. He
found no evidence for a propagation of RNAi (sec-
ondary siRNA) in human cells.
Stefan Limmer (Ribopharma AG, Bayreuth,
Germany) presented invivo gene silencing through
RNAi. Transgenic mice expressing the green ﬂuo-
rescent protein (GFP) gene were repeatedly injected
with siRNA. A substantial decrease of the GFP
mRNA level was achieved in kidney, heart and
serum. Several other organs (small intestine, pan-
creas, lung and stomach) showed varying degrees
of inhibition, while brain and liver appeared to be
hardly accessible.
Kathrin Heermeier (Aventis Pharma, Frank-
furt, Germany) demonstrated downregulation of
target genes using RNAi in a variety of differ-
ent cells, both of insect and mammalian origin.
The second part of her talk compared antisense
and RNAi data obtained in human endothelial
cells. Gene silencing of comparable levels was
achieved by both methods. While she described
the limitations of both methods as similar (need
for cell transfection and short-lived target pro-
teins), the success rate was higher using siRNA
than antisense.
M. Famulok (University of Bonn, Germany)
demonstrated the activity of intramers expressed by
a transgenic virus using the inhibition of cytohesin
1, a guanine–nucleotide exchange factor, as an
example. Successful aptamers lead to a reorganiza-
tion of the actin cytoskeleton in T cells. Speciﬁcally
binding aptamers can then be utilized to design
allosteric ribozymes that speciﬁcally cleave the tar-
get sequence. These ribozymes can be used in high-
throughput assays for ﬁnding small molecules that
bind the target at the selected domain.
Astrid E. Kl¨ opffer (J. W. Goethe University,
Frankfurt, Germany) reported the synthesis and
incorporation of ﬂuoro-modiﬁed universal bases
into a selected anti-HIV polymerase hammerhead
ribozyme. The substitution with the modiﬁed nucle-
obases resulted only in a small reduction of the
catalytic efﬁciency of the ribozyme. Comparable
results were obtained with a ribozyme containing
one mismatch base pair.
Ettore Luzi (Polo Scientiﬁco, Firenze, Italy)
used a library of in vitro selected hammerhead-
like ribozymes with randomised arms to identify
ribozyme-accessible sites on the HIV-1 LTR. A
modiﬁed ribozyme with 2  modiﬁcations and phos-
phorothioate groups was designed against such a
site. The modiﬁed ribozyme showed an extended
range of triplets that could be cleaved.
Round table discussion
Friday evening was reserved for a round table
discussion with no predetermined topic. RNAi,
and how it compares to the other methods, was
the major focus of the evening. For a while, the
debate revolved around the presence or absence
of RNA-dependent RNA-polymerase (RdRP) in
various organisms that may or may not have a
role in RNAi. There was consensus that RdRP
is present in plants and in C. elegans; there is
no deﬁnitive proof for RdRP activity in either
Drosophila or mammals.
The pros and cons of antisense and RNAi
in the experimental knock-down of targets was
another controversial topic. All agreed that the
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lack of certain design rules that would reliably
result in effective oligonucleotides is a problem in
both techniques.
Since the ﬁrst results using RNAi in vivo are
out, the round table speculated on the possibility
of using RNAi in therapy. Potential side effects
could occur: when the system is ﬂooded with
siRNA, the naturally occurring RNA degradation
by microRNA might be compromised.
Session on alternative approaches for
gene silencing
The session started with John J. Rossi (Beckman
Research Institute of the City of Hope, CA,
USA). His main interest is centred on gene therapy
approaches directed towards HIV. Here he uses
CD 34+ haematopoietic stem cells, which are
transduced by tat or rev speciﬁc ribozyme carrying
vectors. These constructs have been in clinical
evaluation for 2 years. Since it is obvious now
that Tat and Rev proteins have nuclear localization,
the group developed Pol III expression systems
where an anti-HIV ribozyme is in the context of
U16 snoRNA. They also constructed vectors based
on Pol III expression to deliver 21–23 nt RNAs
into the nucleus. Here for the ﬁrst time a 4-log
reduction in p24 antigen production was observed
for weeks. For therapeutic purposes, combinations
of ribozymes and RNAi, for example, or even
decoys, are a future line of research.
The advantages of structured RNAs for binding
cellular targets (so-called ‘aptamers’) have been
addressed by Jean-Jacques Toulm´ e (University
of Bordeaux, France). They selected aptamers
against HIV-TAR and found a complementary
59 nt hairpin to the apical loop. The RNA aptamer,
which had a G-A pair closing the loop, had an
afﬁnity (Kd) of 20 nM. When trying to stabi-
lize the aptamer by chemical modiﬁcation, the
L-enantiomer failed, but the 3 -5 -phosporamidate
was successful. It was not only comparably bioac-
tive, but also nuclease-resistant. The above con-
cept also holds true for silencing hepatitis C virus
RNA. Here addressing the 3 -untranslated region,
an aptamer with 70 nM Kd could be obtained.
Stefan Schulte-Merker (Artemis/Exelixis, T¨ u-
bingen, Germany) presented a functional geno-
mics approach in a whole organism. Here zebraﬁsh
were used for reverse genetics. Injecting 25-
mer morpholino-based antisense oligonucleotides
(directed against the 5  UTR) into zebraﬁsh
embryos resulted in up to 98% silencing. The
effect is active after 10 h, and lasts up to 5 days.
Their main effort is now directed towards studying
angiogenesis, e.g. VEGF knockouts. Altogether,
4531 genomes were screened and 746 mutants
selected; 150 genes have been isolated.
Following this, the latest developments in the
chemical synthesis of antisense oligos were pre-
sented. Here the hexitol nucleic acids (HNA) and
the locked nucleic acids (LNA) were discussed
by Piet Herdewijn (Medical Chemistry, Leu-
ven, Belgium) and Jesper Wengel (Odense Uni-
versity, Denmark), respectively. Piet Herdewijn
tested hexo-pyranose analogues and found that
HNA was a powerful steric blocker for mRNA,
and a poor substrate for RNase H. He also showed
that HNA triphosphates are accepted by Vent-
Polymerase.
Jesper Wengel ﬁxed the ribose moiety of RNA in
the A form, using a 2 -4 -bridge. Such structurally
preformed nucleosides are very strong RNA-
binders (conformationally or entropically driven).
NMR structures have been shown to support their
ideal conformation. Since they are not a substrate
for RNase H, they are used as gap-mers to inhibit
mRNA. Some cell experiments using the oestrogen
receptor in MCF-7 cells convincingly showed their
antisense potential. These LNA-analogues seem
to be excellent candidates to be combined with
other modiﬁcations in order to stabilize the oligo-
RNA hybrids.
Concluding remarks
This workshop brought together scientists involved
in the synthesis of nucleic acids with scien-
tists that use their results. Perhaps as a conse-
quence discussions were particularly lively and
fruitful. The workshop was small (approximately
50 participants) and the topic of antisense-based
techniques rather speciﬁc. Since equal time was
given to presentations and discussions, there was
room for detailed discussions of experimental
approaches and possible future improvements.
Originally we had planned to cover several dif-
ferent techniques with equal weight within the
workshop. However, after the invited speakers
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had sent in the titles of their talks it turned out
that RNAi was the centre of attention for many
researchers. Therefore, two of the four sessions
were devoted to this technique. RNAi represents
the latest development in the ﬁeld of downregula-
tion of gene expression through sequence-speciﬁc
recognition. The recent shift of interest towards
RNAi illustrates both the speed with which the
ﬁeld changes, and how difﬁcult it is to plan for
the future. If a similar workshop is to be orga-
nized 2 years from now, what should the focus be?
The participants of the workshop were unable to
predict this. While technologies change, there will
certainly be interest in studies of gene function for
some time to come and we will continue to knock
down genes one way or the other.
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